Danxin Wang, M.D., Ph.D.

Danxin Wang

Associate Professor

Pharmacotherapy and Translational Research

OFFICE: HSC PG-05B

EMAIL: danxin.wang@cop.ufl.edu

PHONE: 352-273-7673

CV: Link to CV

 

Education

M.D.    Fudan University Medical School, Shanghai, China

M.S.     Fudan University Medical School, Shanghai, China (Pharmacology)

Ph.D.   Academy of Military Medical Sciences, Beijing, China (Pharmacology)

NIH/NIDA INVEST Research Fellow   University of California San Francisco, California

 

Biographical sketch

Dr. Wang received her MD degree from Fudan University Medical School and her Ph.D from the Academy of Military Medical Science in Beijing. She did postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics and Associate Director of Center for Pharmacogenomics prior to joining the University of Florida.

Dr. Wang’s research interests are the discovery of genetic biomarkers for personalized drug therapy.  She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases and drug dependence.  Some of these functional variants are currently included in biomarker testing panels to predict drug response.

Funded by NIH R01 award, “Expression genetics of CYP3A drug metabolizing enzymes”, Dr. Wang’s current research is to understand factors controlling the expression of CYP3A, the main drug metabolizing enzyme in the liver.  Using recently developed cutting edge functional genetics/genomics approaches, the research will focus on understanding what genetic, epigenetic and non-genetic factors may contribute to CYP3A variability, with the goal to identify biomarker predicting CYP3A enzyme activity for personalized therapy of nearly 50% of currently used medications.

Dr. Wang has served as an Associate Editor of “European Journal of Pharmaceutical Sciences” and was on editorial Board of “Journal of Pharmacogenomics and Pharmacoproteomics”.  She has also served as grant reviewer for NIH.

 

Professional Affiliations

American Society for Human Genetics (ASHG)

American Society of Pharmacology Experimental Therapeutics (ASPET)

International Society for the Study of Xenobiotics (ISSX)

Pharmacogenomics Research Network (PGRN)

 

Selected publications

(1) D. Wang, Y. Guo, S.A. Wrighton, G.E. Cooke and W. Sadee.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.  The Pharmacogenomics J.  11(4):274-286, 2011, PMID 20386561, PMC3248744

(2) D. Wang, M.J Poi, X. Sun, A. Gaedigk, J.S. Leeder, W. Sadee.  Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Human Molecular Genetics, 23(1): 268-278, 2014.  PMID: 23985325, PMC3857955

(3) L. Li, L. Zhang, P.F. Binkley, W. Sadee and D. Wang.  Regulatory variants modulate protein kinase C alpha (PRKCA) gene expression in human heart. Pharm Res.  34:1648-1657, 2017. PMID: 28120175

(4) D. Wang, K. Hartmann, M. Seweryn and W. Sadee.  Interactions between regulatory variants in CYP7A1 (Cholesterol 7a-hydroxylase) promoter and enhancer regions regulate CYP7A1 expression.  Circ. Genom Precis Med.  11(10): e002082, 2018, PMID: 30354296

(5) B. Ray, E. Ozcagli, W. Sadee and D. Wang.  CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotype panels.  Pharmacogenet Genomics  29(2): 39-47, 2019, PMID: 30520769

 

Complete List of Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/myncbi/danxin.wang.1/bibliography/public/